La articulación público-privada en la producción de vacunas en México

Abstract

This paper analyzes the process of privatization of health care services through the Public-Private Articulation (APA). The production of vaccines in Mexico is studied through the case study of Biological and Reagents Laboratories of Mexico, LLC (Birmex), company responsible for the production, distribution and research of biologicals and reagents in Mexico. We specifically focused on Birmex's performance during the Influenza A, subtype H1N1 virus pandemic. The results show that as a result of the liberalization and deregulation policies, there is an opening of public services to supranational corporations. KEYWORDS

Economic Impact of Local Vaccine Manufacturing

“…• Public-private partnerships (PPPs) are vital for Thailand to accelerate vaccine development and production. However, this did not work for Mexico due to a history of political instability (Carrillo, 2017) -from the standpoint of self-sufficiency, not enough vaccines have been produced since 1998 (Tamez et al, 2016).…”

“…Mexico had achieved self-sufficiency in vaccine production, control, storage and distribution, except in the case of the poliomyelitis vaccine, whose production did not always fulfil national demand, and by the end of the 1980s was exporting biological products (including vaccines, mainly for rabies) to fifteen countries in the Caribbean as well as Central and Latin America (Carrillo, 2017: 135). However, from the standpoint of self-sufficiency, not enough vaccines have been produced since 1998 (Tamez et al, 2016).…”

Vaccine market and production capabilities in the Americas

“…In 1970 the WHO recognized the National Institute of Virology as a regional reference center for vaccines. This governmental institution produces vaccines against rabies, MCV, tetanus, and poliomyelitis, covering approximately 90% of vaccines required from 1956 to 1960 [ 31 ].…”

“…The company is responsible for manufacturing 25 million OPV doses and 12 million DT doses, which covers the national demand. Birmex plants can produce up to 100 million vaccines a year, as well as two antidotes against the venom of Scorpion and vipers [ 31 ].…”

“…According to data from the national pharmaceutical bureau, the Cuban pharmaceutical industry generated more than 2.7 billion dollars in pharmaceutical products from 2008 to 2013, a remarkable amount considering that Cuban products are exported to many countries in the world [ 31 – 33 ].…”